PMID: 9175616Mar 1, 1997Paper

Modulation of the discriminative stimulus properties of cocaine: comparison of the effects of fluoxetine with 5-HT1A and 5-HT1B receptor agonists

Neuropharmacology
P M Callahan, K A Cunningham

Abstract

The present investigation examined the ability of serotonin (5-HT) agonists to substitute for, or alter (i.e. enhance or antagonize), the discriminative stimulus properties of a moderately low dose of cocaine (5 mg/kg) utilizing a two-lever, water-reinforced FR 20 drug discrimination procedure in rats. In substitution tests, the 5-HT1A receptor partial agonists buspirone and gepirone, the 5-HT1A/B receptor agonist RU 24969 and the 5-HT1B/2C receptor agonist m-trifluoromethyl-phenylpiperazine (TFMPP) failed to substitute for the cocaine stimulus, although RU 24969 did engender a maximum of 72% cocaine-lever responding. Fluoxetine (4 mg/kg) engendered primarily saline-appropriate responding. In combination tests, a fixed dose of either fluoxetine (4 mg/kg), RU 24969 (0.5 mg/kg) or TFMPP (0.5 mg/kg) produced a leftward shift in the cocaine dose-response curve (0.313-5 mg/kg). In contrast, buspirone (2.5-20 mg/kg) resulted in a dose-dependent attenuation (approximately 60% reduction) of the cocaine stimulus. Moreover, a dose of 10 mg/kg of buspirone co-administered with various doses of cocaine (1.25-10 mg/kg) engendered a rightward shift in the cocaine dose-response curve. Gepirone in combination with cocaine neither enhanced nor ...Continue Reading

References

Jul 1, 1992·Journal of Pharmacological and Toxicological Methods·H T ChenD Goldman
Jul 23, 1991·European Journal of Pharmacology·S Benloucif, M P Galloway
Jan 1, 1991·Psychopharmacology·J L KatzJ M Witkin
Jun 12, 1990·European Journal of Pharmacology·I van WijngaardenW Soudijn
Jan 1, 1990·Pharmacology, Biochemistry, and Behavior·J B Kamien, W L Woolverton
Dec 1, 1987·Journal of Clinical Psychopharmacology·R W Fuller, D T Wong
Jan 1, 1988·Psychopharmacology·M CarliR Samanin
Jul 14, 1988·European Journal of Pharmacology·A Goudie, D Reid
Jan 1, 1982·Progress in Neuro-psychopharmacology & Biological Psychiatry·J Hyttel
Jan 1, 1983·Journal of Neural Transmission·B A McMillen, L A Mattiace
Jan 1, 1981·Psychopharmacology·K Extance, A J Goudie
Mar 1, 1980·Neuropharmacology·M L McKenna, B T Ho
Jun 1, 1994·Pharmacology, Biochemistry, and Behavior·R L PeltierS Schenk
Jul 1, 1997·Pharmacology, Biochemistry, and Behavior·P M CallahanK A Cunningham

❮ Previous
Next ❯

Citations

Jun 30, 2001·European Journal of Pharmacology·E PrzegalinskiM Filip
Jan 14, 2003·European Journal of Pharmacology·Małgorzata FilipEdmund Przegaliński
Dec 22, 2000·Pharmacology, Biochemistry, and Behavior·P W Czoty, L L Howell
Mar 20, 2002·Pharmacology, Biochemistry, and Behavior·Robert J CareyErnest Damianopoulos
Oct 9, 1999·Pharmacology, Biochemistry, and Behavior·N van CampenhoutT F Meert
Feb 21, 2002·Behavioural Brain Research·Robert J CareyErnest Damianopoulos
Sep 5, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Edmund PrzegalińskiMałgorzata Filip
Oct 18, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nancy K MelloJack Bergman
Jan 23, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nancy K MelloStephen J Kohut
Jul 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Joshua A LileCraig R Rush
May 10, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Janusz BoryczSergi Ferré
Jun 9, 2001·Behavioural Pharmacology·E PrzegalinskiJ Siwanowicz
Mar 3, 2010·Behavioural Pharmacology·Paul L SotoJonathan L Katz
Aug 5, 2009·Addiction Biology·Nathan S PentkowskiJanet L Neisewander
May 12, 2010·Addiction Biology·Małgorzata FilipEdmund Przegaliński
Dec 16, 2005·The AAPS Journal·Thomas E PrisinzanoWayne W Harding
Feb 5, 2013·Drug and Alcohol Dependence·Keith L SheltonPatrick M Beardsley
Dec 23, 2008·Pharmacology, Biochemistry, and Behavior·Paul L Soto, Jonathan L Katz
Feb 24, 2007·Progress in Neurobiology·Christian P MüllerMaria A De Souza Silva
Feb 1, 2005·Pharmacology, Biochemistry, and Behavior·Jazmin I AcostaJanet L Neisewander
Oct 20, 2006·Pharmacology & Therapeutics·K D Alex, E A Pehek
Jan 13, 2006·Trends in Pharmacological Sciences·Christian P Müller, Joseph P Huston
Apr 29, 2014·Behavioural Brain Research·Christian P Müller, Judith R Homberg
Dec 24, 2013·The American Journal of Drug and Alcohol Abuse·Neil E PatersonEdythe D London
Jul 26, 2012·The International Journal of Neuropsychopharmacology·Jack BergmanPhil Skolnick
Sep 6, 2008·Progress in Brain Research·Marcy J Bubar, Kathryn A Cunningham
Jul 10, 2007·European Journal of Pharmacology·Magdalena ZaniewskaMalgorzata Filip
Dec 17, 2014·Pharmacological Reviews·Leonard L Howell, Kathryn A Cunningham
Jul 9, 2004·The Journal of Pharmacology and Experimental Therapeutics·Paul W CzotyJack Bergman
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Alan P KozikowskiSrihari R Tella

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.